104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026 HB3134 Introduced , by Rep. Hoan Huynh SYNOPSIS AS INTRODUCED: New Act Creates the Canadian Prescription Drug Importation Act. Provides that the Department of Public Health shall establish the Canadian prescription drug importation program for the importation of safe and effective prescription drugs from Canada which have the highest potential for cost savings to the State. Provides that the Department shall contract with a vendor to provide services under the program. Provides that by December 1, 2026 and each year thereafter, the vendor shall develop a wholesale prescription drug importation list identifying the prescription drugs that have the highest potential for cost savings to the State. Provides that the vendor shall identify Canadian suppliers that are in full compliance with the provisions of the Act and contract with the Canadian suppliers to import drugs under the program. Provides for: a bond requirement; requirements for eligible prescription drugs; requirements for eligible Canadian suppliers; requirements for eligible importers; distribution requirements; federal approval; prescription drug supply chain documentation; immediate suspension of specified imported drug; requirements of an annual report; notification of federal approval. Provides that the Department shall adopt rules necessary to implement the Act. Effective immediately. LRB104 09684 BAB 19750 b A BILL FOR 104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026 HB3134 Introduced , by Rep. Hoan Huynh SYNOPSIS AS INTRODUCED: New Act New Act Creates the Canadian Prescription Drug Importation Act. Provides that the Department of Public Health shall establish the Canadian prescription drug importation program for the importation of safe and effective prescription drugs from Canada which have the highest potential for cost savings to the State. Provides that the Department shall contract with a vendor to provide services under the program. Provides that by December 1, 2026 and each year thereafter, the vendor shall develop a wholesale prescription drug importation list identifying the prescription drugs that have the highest potential for cost savings to the State. Provides that the vendor shall identify Canadian suppliers that are in full compliance with the provisions of the Act and contract with the Canadian suppliers to import drugs under the program. Provides for: a bond requirement; requirements for eligible prescription drugs; requirements for eligible Canadian suppliers; requirements for eligible importers; distribution requirements; federal approval; prescription drug supply chain documentation; immediate suspension of specified imported drug; requirements of an annual report; notification of federal approval. Provides that the Department shall adopt rules necessary to implement the Act. Effective immediately. LRB104 09684 BAB 19750 b LRB104 09684 BAB 19750 b A BILL FOR
104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026 HB3134 Introduced , by Rep. Hoan Huynh SYNOPSIS AS INTRODUCED:
New Act New Act
New Act
Creates the Canadian Prescription Drug Importation Act. Provides that the Department of Public Health shall establish the Canadian prescription drug importation program for the importation of safe and effective prescription drugs from Canada which have the highest potential for cost savings to the State. Provides that the Department shall contract with a vendor to provide services under the program. Provides that by December 1, 2026 and each year thereafter, the vendor shall develop a wholesale prescription drug importation list identifying the prescription drugs that have the highest potential for cost savings to the State. Provides that the vendor shall identify Canadian suppliers that are in full compliance with the provisions of the Act and contract with the Canadian suppliers to import drugs under the program. Provides for: a bond requirement; requirements for eligible prescription drugs; requirements for eligible Canadian suppliers; requirements for eligible importers; distribution requirements; federal approval; prescription drug supply chain documentation; immediate suspension of specified imported drug; requirements of an annual report; notification of federal approval. Provides that the Department shall adopt rules necessary to implement the Act. Effective immediately.
LRB104 09684 BAB 19750 b LRB104 09684 BAB 19750 b
LRB104 09684 BAB 19750 b
A BILL FOR
HB3134LRB104 09684 BAB 19750 b HB3134 LRB104 09684 BAB 19750 b
HB3134 LRB104 09684 BAB 19750 b
1 AN ACT concerning health.
2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
4 Section 1. Short title. This Act may be cited as the
5 Canadian Prescription Drug Importation Act.
6 Section 5. Legislative findings. The General Assembly
7 finds:
8 (1) United States consumers pay some of the highest
9 prescription drug prices in the world, and it is estimated
10 that United States consumers pay twice as much as the amount
11 Canadian consumers pay for patented prescription drugs and 20%
12 more for generic drugs.
13 (2) Federal law, as codified in 21 U.S.C. 384, authorizes
14 the Secretary of the United States Department of Health and
15 Human Services to allow wholesale importation of prescription
16 drugs from Canada if such importation is shown to be both safe
17 and less costly for United States consumers.
18 (3) Although importing prescription drugs would be less
19 costly, there may be risks posed to consumer health and safety
20 if the source, quality, and purity of prescription drugs sold
21 by online pharmacies cannot be verified.
22 (4) Canada has a rigorous regulatory system to license
23 prescription drugs, equivalent to the licensing system in the
104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026 HB3134 Introduced , by Rep. Hoan Huynh SYNOPSIS AS INTRODUCED:
New Act New Act
New Act
Creates the Canadian Prescription Drug Importation Act. Provides that the Department of Public Health shall establish the Canadian prescription drug importation program for the importation of safe and effective prescription drugs from Canada which have the highest potential for cost savings to the State. Provides that the Department shall contract with a vendor to provide services under the program. Provides that by December 1, 2026 and each year thereafter, the vendor shall develop a wholesale prescription drug importation list identifying the prescription drugs that have the highest potential for cost savings to the State. Provides that the vendor shall identify Canadian suppliers that are in full compliance with the provisions of the Act and contract with the Canadian suppliers to import drugs under the program. Provides for: a bond requirement; requirements for eligible prescription drugs; requirements for eligible Canadian suppliers; requirements for eligible importers; distribution requirements; federal approval; prescription drug supply chain documentation; immediate suspension of specified imported drug; requirements of an annual report; notification of federal approval. Provides that the Department shall adopt rules necessary to implement the Act. Effective immediately.
LRB104 09684 BAB 19750 b LRB104 09684 BAB 19750 b
LRB104 09684 BAB 19750 b
A BILL FOR
New Act
LRB104 09684 BAB 19750 b
HB3134 LRB104 09684 BAB 19750 b
HB3134- 2 -LRB104 09684 BAB 19750 b HB3134 - 2 - LRB104 09684 BAB 19750 b
HB3134 - 2 - LRB104 09684 BAB 19750 b
1 United States.
2 (5) In the United States, Title II of the federal Drug
3 Quality and Security Act, referred to as the Drug Supply Chain
4 Security Act, has significantly improved drug security and
5 safety through a system of pharmaceutical product
6 track-and-trace procedures.
7 (6) A wholesale drug importation program for the exclusive
8 benefit of residents of the State should be designed and
9 implemented to provide consumers of the State access to safe
10 and less expensive prescription drugs.
11 Section 10. Definitions. As used in this Act:
12 "Canadian supplier means a manufacturer, wholesale
13 distributor, or pharmacy that is appropriately licensed or
14 permitted under Canadian federal and provincial laws and
15 regulations to manufacturer, distribute, or dispense
16 prescription drugs.
17 "Department" means the Department of Public Health.
18 "Drug" or prescription drug" has has the same meaning as
19 "drugs" in Section 1 of the Pharmacy Practice Act.
20 "Eligible importer" means an importer that is:
21 (1) a pharmacist or wholesaler employed by or under
22 contract with a medicaid pharmacy, for dispensing to the
23 pharmacy's medicaid recipients;
24 (2) a pharmacist or wholesaler employed by or under
25 contract with the Department of Corrections, for
HB3134 - 2 - LRB104 09684 BAB 19750 b
HB3134- 3 -LRB104 09684 BAB 19750 b HB3134 - 3 - LRB104 09684 BAB 19750 b
HB3134 - 3 - LRB104 09684 BAB 19750 b
1 dispensing to inmates in the custody of the Department of
2 Corrections;
3 (3) a commercial plan, as defined by rules adopted by
4 the Department and as approved by the federal government;
5 and
6 (4) a licensed pharmacist under the Pharmacy Practice
7 Act or registered wholesaler approved by the Department.
8 "Federal act" means the federal Food, Drug, and Cosmetic
9 Act.
10 "Medicaid pharmacy means a pharmacy licensed under the
11 Pharmacy Practice Act that has a Medicaid provider agreement
12 in effect with the State and is in good standing with the
13 State.
14 "Pharmacist" means a person who holds and active and
15 unencumbered license to practice pharmacy under the Pharmacy
16 Practice Act.
17 "Program" means the Canadian prescription drug importation
18 program created in this Act.
19 "Vendor" means a vendor with which the State who contracts
20 for the provision of services under the program pursuant to
21 subsection (a) of Section 15.
22 Section 15. Canadian prescription drug importation
23 program; importation process; contract with vendor; vendor
24 duties.
25 (a) The Canadian prescription drug importation program is
HB3134 - 3 - LRB104 09684 BAB 19750 b
HB3134- 4 -LRB104 09684 BAB 19750 b HB3134 - 4 - LRB104 09684 BAB 19750 b
HB3134 - 4 - LRB104 09684 BAB 19750 b
1 created in the Department. Upon receiving approval of the
2 program as described in Section 25, the Department shall
3 contract with one or more vendors to provide services under
4 the program. For 3 years following the effective date of this
5 Act, the selection of any vendor pursuant to this subsection
6 is exempt from the requirements of the Illinois Procurement
7 Code.
8 (b) Each vendor, in consultation with the Department and
9 any other vendors, shall establish a wholesale prescription
10 drug importation list that identifies the prescription drugs
11 that have the highest potential for cost savings to the State.
12 In developing the list, each vendor shall consider, at a
13 minimum, which prescription drugs will provide the greatest
14 cost savings to the State, including prescription drugs for
15 which there are shortages, specialty prescription drugs, and
16 high-volume prescription drugs. Each vendor shall revise the
17 list at least annually and at the direction of the State
18 department pursuant to this subsection. The Department shall
19 review the wholesale prescription drug importation list at
20 least every 3 months to ensure that it continues to meet the
21 requirements of the program. The Department may direct a
22 vendor to revise the list, as necessary. Each vendor, in
23 consultation with the Department, shall identify Canadian
24 suppliers who are in full compliance with relevant Canadian
25 federal and provincial laws and regulations and who have
26 agreed to export prescription drugs identified on the
HB3134 - 4 - LRB104 09684 BAB 19750 b
HB3134- 5 -LRB104 09684 BAB 19750 b HB3134 - 5 - LRB104 09684 BAB 19750 b
HB3134 - 5 - LRB104 09684 BAB 19750 b
1 wholesale prescription drug importation list. Each vendor
2 shall verify that such Canadian suppliers meet all of the
3 requirements of the program and will export prescription drugs
4 at prices that will provide cost savings to the State. Each
5 vendor shall contract with such eligible Canadian suppliers,
6 or facilitate contracts between eligible importers and
7 Canadian suppliers, to import prescription drugs under the
8 program. Each vendor shall assist the Department in developing
9 and administering a distribution program within the program.
10 Each vendor shall assist the Department with the annual report
11 described in this Act and provide any information requested by
12 the Department for the report. Each vendor shall ensure the
13 safety and quality of drugs imported under the program, as
14 follows:
15 (1) for an initial imported shipment, ensure that each
16 batch of the drug in the shipment is statistically sampled
17 and tested for authenticity and degradation in a manner
18 consistent with the federal act, and for any subsequent
19 imported shipment, ensure that a statistically valid
20 sample of the shipment is tested for authenticity and
21 degradation in a manner consistent with the federal act;
22 (2) certify that each drug: (i) is approved for
23 marketing in the United States and is not adulterated or
24 misbranded; and (ii) meets all of the labeling
25 requirements under 21 U.S.C. 352;
26 (3) maintain qualified laboratory records, including
HB3134 - 5 - LRB104 09684 BAB 19750 b
HB3134- 6 -LRB104 09684 BAB 19750 b HB3134 - 6 - LRB104 09684 BAB 19750 b
HB3134 - 6 - LRB104 09684 BAB 19750 b
1 complete data derived from all tests necessary to ensure
2 that the drug is in compliance with the requirements of
3 this Section; and
4 (4) maintain documentation demonstrating that the
5 testing required by this Section was conducted at a
6 qualified laboratory in accordance with the Federal Act
7 and any other applicable federal and State laws and
8 regulations governing laboratory qualifications.
9 (c) All testing required by this section must be conducted
10 in a qualified laboratory that meets the standards under the
11 Federal Act and any other applicable federal and State laws
12 and regulations governing laboratory qualifications for drug
13 testing.
14 (d) Each vendor shall maintain a list of all eligible
15 importers that participate in the program.
16 (e) Each vendor shall ensure compliance with Title II of
17 the federal Drug Quality and Security Act by all Canadian
18 suppliers, eligible importers, distributors, and other
19 participants in the program.
20 (f) Each vendor shall provide an annual financial audit of
21 its operations to the Department. Each vendor shall also
22 provide quarterly financial reports specific to the program
23 and shall include information concerning the performance of
24 its subcontractors and vendors. The Department shall determine
25 the format and contents of the reports.
26 (g) Each vendor shall submit evidence of a surety bond
HB3134 - 6 - LRB104 09684 BAB 19750 b
HB3134- 7 -LRB104 09684 BAB 19750 b HB3134 - 7 - LRB104 09684 BAB 19750 b
HB3134 - 7 - LRB104 09684 BAB 19750 b
1 with any bid or initial contract negotiation documents and
2 shall maintain documentation of evidence of such a bond with
3 the Department throughout the contract term. The surety bond
4 may be from this State or any other State in the United States
5 and must be in an amount of at least $25,000. The surety bond
6 or comparable security arrangement must include the State as a
7 beneficiary. In lieu of the surety bond, a vendor may provide a
8 comparable security agreement, such as an irrevocable letter
9 of credit or a deposit into a trust account or financial
10 institution that includes the State as a beneficiary, payable
11 to the State. The purposes of the bond or other security
12 arrangement are to:
13 (1) ensure participation of the vendor in any civil or
14 criminal legal action by the State department, any other
15 State agency, or private individuals or entities against
16 the vendor because of the vendor's failure to perform
17 under the contract, including, but not limited to, causes
18 of actions for personal injury, negligence, and wrongful
19 death;
20 (2) ensure payment by the vendor through the use of a
21 bond or other comparable security arrangement of any legal
22 judgments and claims that are awarded to the State, other
23 entities acting on behalf of the State, individuals, or
24 organizations if the vendor is assessed a final judgment
25 or other monetary penalty in a court of law for a civil or
26 criminal action under the program. The bond or comparable
HB3134 - 7 - LRB104 09684 BAB 19750 b
HB3134- 8 -LRB104 09684 BAB 19750 b HB3134 - 8 - LRB104 09684 BAB 19750 b
HB3134 - 8 - LRB104 09684 BAB 19750 b
1 security arrangement may be accessed if the vendor fails
2 to pay any judgment or claim within 60 days after final
3 judgment; and
4 (3) allow for civil and criminal litigation claims to
5 be made against the bond or other comparable security
6 arrangements for up to one year after the vendor's
7 contract under the program has ended with the Department,
8 the vendor's license is no longer valid, or the program
9 has ended, whichever occurs last.
10 (8) Each vendor shall maintain information and
11 documentation submitted under this Section for a period of at
12 least 7 years.
13 (9) The Department may require each vendor to collect any
14 other information necessary to ensure the protection of the
15 public health.
16 Section 20. Eligible prescription drugs; eligible Canadian
17 suppliers; eligible importers; distribution requirements.
18 (a) An eligible importer may import a prescription drug
19 from a Canadian supplier if:
20 (1) the drug meets the United States Food and Drug
21 Administration's standards related to safety,
22 effectiveness, misbranding, and adulteration;
23 (2) importing the drug would not violate federal
24 patent laws;
25 (3) importing the drug is expected to generate cost
HB3134 - 8 - LRB104 09684 BAB 19750 b
HB3134- 9 -LRB104 09684 BAB 19750 b HB3134 - 9 - LRB104 09684 BAB 19750 b
HB3134 - 9 - LRB104 09684 BAB 19750 b
1 savings; and
2 (4) the drug is not:
3 (i) a controlled substance as defined in 21 U.S.C.
4 802;
5 (ii) a biological product as defined in 42 U.S.C.
6 262;
7 (iii) an infused drug;
8 (iv) an intravenously injected drug;
9 (v) a drug that is inhaled during surgery; or
10 (vi) a drug that is a parenteral drug, the
11 importation of which is determined by the United
12 States Secretary of Health and Human Services to pose
13 a threat to the public health.
14 (b) A Canadian supplier may export prescription drugs into
15 the State under the program if the supplier:
16 (1) is in full compliance with relevant Canadian
17 federal and provincial laws and regulations;
18 (2) is identified by the vendor as eligible to
19 participate in the program; and
20 (3) submits an attestation that the supplier has a
21 registered agent in the United States, including the name
22 and United States address of the registered agent.
23 (c) The following entities are eligible importers and may
24 obtain imported prescription drugs:
25 (1) a pharmacist or wholesaler employed by or under
26 contract with a Medicaid pharmacy, for dispensing to the
HB3134 - 9 - LRB104 09684 BAB 19750 b
HB3134- 10 -LRB104 09684 BAB 19750 b HB3134 - 10 - LRB104 09684 BAB 19750 b
HB3134 - 10 - LRB104 09684 BAB 19750 b
1 pharmacy's Medicaid recipients;
2 (2) a pharmacist or wholesaler employed by or under
3 contract with the Department of Corrections, for
4 dispensing to inmates in the custody of the Department of
5 Corrections;
6 (3) commercial plans, as defined by rules promulgated
7 by the State Board and as approved by the federal
8 government; and
9 (4) a licensed pharmacist or wholesaler approved by
10 the Department under the Pharmacy Practice Act.
11 (d) The Department shall designate an office or division
12 that must be a licensed pharmaceutical wholesaler or that
13 shall contract with a licensed pharmaceutical wholesaler
14 licensed pursuant to Part 3 of Article 42.5 of Title 12. The
15 office or division designated by the Department shall:
16 (1) set a maximum profit margin so that a wholesaler,
17 distributor, pharmacy, or other licensed provider
18 participating in the program maintains a profit margin
19 that is no greater than the profit margin that the
20 wholesaler, distributor, pharmacy, or other licensed
21 provider whole have earned on the equivalent nonimported
22 drug;
23 (2) exclude generic products if the importation of the
24 products would violate United States patent laws
25 applicable to United States-branded products;
26 (3) comply with the requirements of 21 U.S.C. 360eee
HB3134 - 10 - LRB104 09684 BAB 19750 b
HB3134- 11 -LRB104 09684 BAB 19750 b HB3134 - 11 - LRB104 09684 BAB 19750 b
HB3134 - 11 - LRB104 09684 BAB 19750 b
1 through 360eee-4 as enacted in Title II of the federal
2 Drug Quality and Security Act; and
3 (4) determine a method for covering the administrative
4 costs of the program, which method may include a fee
5 imposed on each prescription pharmaceutical product sold
6 through the program or any other appropriate method as
7 determined by the Department, but the Department shall not
8 require a fee in an amount the Department determines would
9 significantly reduce consumer savings.
10 (e) Canadian suppliers and eligible importers
11 participating under the program:
12 (1) shall comply with the tracking and tracing
13 requirements of 21 U.S.C. 360; and
14 (2) shall not distribute, dispense, or sell
15 prescription drugs imported under the program outside of
16 the State.
17 (f) A participating eligible importer shall submit to the
18 vendor all of the following information about each drug to be
19 acquired by the importer under the program:
20 (1) the name and quantity of the active ingredient of
21 the drug;
22 (2) a description of the dosage form of the drug;
23 (3) the date on which the drug is received;
24 (4) the quantity of the drug that is received;
25 (5) the point of origin and destination of the drug;
26 and
HB3134 - 11 - LRB104 09684 BAB 19750 b
HB3134- 12 -LRB104 09684 BAB 19750 b HB3134 - 12 - LRB104 09684 BAB 19750 b
HB3134 - 12 - LRB104 09684 BAB 19750 b
1 (6) the price paid by the importer for the drug.
2 (g) A participating Canadian supplier shall submit to the
3 vender the following information about each drug to be
4 supplied by the Canadian supplier under the program:
5 (1) the original source of the drug, including:
6 (i) the name of the manufacturer of the drug;
7 (ii) the date on which the drug was manufactured;
8 and
9 (iii) the location including the country, state or
10 province, and city, where the drug was manufactured;
11 (2) the date on which the drug is shipped;
12 (3) the quantity of the drug that is shipped;
13 (4) the quantity of each lot of the drug originally
14 received and the source of the lot; and
15 (5) the lot or control number and the batch number
16 assigned to the drug by the manufacturer.
17 (h) The Department shall immediately suspend the
18 importation of a specific drug or the importation of drugs by a
19 specific eligible importer if it discovers that any drug or
20 activity is in violation of this Section or any federal or
21 State law or regulation. The Department may revoke the
22 suspension if, after conducting an investigation, it
23 determines that the public is adequately protected from
24 counterfeit or unsafe drugs being imported into this State.
25 Section 25. Federal approval.
HB3134 - 12 - LRB104 09684 BAB 19750 b
HB3134- 13 -LRB104 09684 BAB 19750 b HB3134 - 13 - LRB104 09684 BAB 19750 b
HB3134 - 13 - LRB104 09684 BAB 19750 b
1 (a) On or before September 1, 2025, the Department shall
2 submit a request to the United States Secretary of Health and
3 Human Services for approval of the program under 21 U.S.C.
4 384. The Department shall begin operating the program within 6
5 months after receiving such approval. The request must, at a
6 minimum:
7 (1) describe the Department's plan for operating the
8 program;
9 (2) demonstrate how the prescription drugs imported
10 into this State under the program will meet the applicable
11 federal and State standards for safety, effectiveness,
12 misbranding, and adulteration;
13 (3) include a list of proposed prescription drugs that
14 have the highest potential for cost savings to the State
15 through importation at the time that the request is
16 submitted;
17 (4) estimate the total cost savings attributable to
18 the program;
19 (5) include a list of potential Canadian suppliers
20 from which the State would import drugs and demonstrate
21 that the suppliers are in full compliance with relevant
22 Canadian federal and provincial laws and regulations.
23 (b) Notwithstanding any provision of this subsection to
24 the contrary, the Department may expend money for the purpose
25 of requesting approval of the program as described in
26 subsection (a), but the Department shall not spend any other
HB3134 - 13 - LRB104 09684 BAB 19750 b
HB3134- 14 -LRB104 09684 BAB 19750 b HB3134 - 14 - LRB104 09684 BAB 19750 b
HB3134 - 14 - LRB104 09684 BAB 19750 b
1 money to implement the program until the Department receives
2 approval of the program as described in subsection (a).
3 (c) Upon receipt of federal approval of the program, the
4 Department shall notify the President of the Senate and the
5 Speaker of the House of Representatives, as well as the Health
6 and Human Services Committee of the Senate and the Health and
7 Insurance Committee of the House of Representatives, or any
8 successor committees. After approval is received and before
9 the start of the next regular session of the General Assembly
10 in which the proposal could be funded, the Department shall
11 submit to all parties specified in this subsection a proposal
12 for program implementation and program funding.
13 Section 30. Reports. On or before December 1, 2026 and on
14 or before December 1 each year thereafter, the Department
15 shall submit a report to the Governor, the President of the
16 Senate, and the Speaker of the House of Representatives on the
17 operation of the program during the previous fiscal year. The
18 report must include, at a minimum:
19 (1) a list of the prescription drugs that were
20 imported under the program;
21 (2) the number of participating Canadian suppliers and
22 eligible importers;
23 (3) the number of prescriptions dispensed through the
24 program;
25 (4) the estimated cost savings during the previous
HB3134 - 14 - LRB104 09684 BAB 19750 b
HB3134- 15 -LRB104 09684 BAB 19750 b HB3134 - 15 - LRB104 09684 BAB 19750 b
HB3134 - 15 - LRB104 09684 BAB 19750 b
1 fiscal year and to date attributable to the program;
2 (5) a description of the methodology used to determine
3 which drugs should be included on the wholesale
4 prescription drug importation list; and
5 (6) documentation as to how the program ensures the
6 following that:
7 (i) Canadian suppliers participating in the
8 program are in full compliance with relevant Canadian
9 federal and provincial laws;
10 (ii) prescription drugs imported under the program
11 are not shipped, sold, or dispensed outside of this
12 State once in the possession of the eligible importer;
13 (iii) prescription drugs imported under the
14 program are pure, unadulterated, potent, and safe;
15 (iv) the program does not put consumers at a
16 higher health and safety risk than if the program did
17 not exist; and
18 (v) the program provides cost savings to the State
19 on imported prescription drugs.
20 Section 35. Importation program authorized; rulemaking.
21 (a) Upon approval by the Secretary, in accordance with
22 Section 30, the Department shall administer an importation
23 program.
24 (b) The Department shall approve a method of financing and
25 administrative costs of the importation program, which method
HB3134 - 15 - LRB104 09684 BAB 19750 b
HB3134- 16 -LRB104 09684 BAB 19750 b HB3134 - 16 - LRB104 09684 BAB 19750 b
HB3134 - 16 - LRB104 09684 BAB 19750 b
1 may include imposing a fee on each prescription pharmaceutical
2 product sold through the importation program or any other
3 appropriate method determined by the Department to finance
4 administrative costs. The Department shall not require a fee
5 in an amount that the Department determines would
6 significantly reduce consumer savings.
7 (c) The Department shall adopt rules necessary to
8 implement this Act.
HB3134 - 16 - LRB104 09684 BAB 19750 b